Latest news with #DelveInsight
Malaysian Reserve
19 hours ago
- Business
- Malaysian Reserve
GPCR-Targeting Therapies Market Poised for Strong Growth During the Forecast Period (2025-2034) Across 7MM Due to the Rising Cancer Diagnoses and Drug Pipeline Expansion
The GPCR-targeting therapies market is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of GPCR-Targeting therapies, and the increasing number of GPCR-Targeting therapies that are under clinical trials and filed for approval by various companies. LAS VEGAS, June 30, 2025 /PRNewswire/ — DelveInsight's GPCR-Targeting Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as PTCL, CTCL, migraine, NASH, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging GPCR-targeting therapies, market share of individual therapies, and current and forecasted GPCR-targeting therapies market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the GPCR-Targeting Therapies Market Report As per DelveInsight's analysis, the total market size of GPCR-targeting therapies in the 7MM is expected to surge significantly by 2034. The United States is expected to hold the largest share of the total GPCR inhibitors market among the 7MM. The report provides the total potential number of patients in the indications, such as PTCL, CTCL, Migraine, NASH, and others. Leading GPCR-targeting therapies companies, such as CytoDyn, REMD Biotherapeutics, GPCR Therapeutics, Structure Therapeutics, and others, are developing novel GPCR-targeting therapies that can be available in the GPCR-targeting therapies market in the coming years. Some of the key GPCR-targeting therapies in the pipeline include Leronlimab, Volagidemab, GPC-100, GSBR-1290, and others. In July 2024, Radionetics Oncology entered into a strategic agreement with Eli Lilly and Company, providing Lilly access to Radionetics' proprietary GPCR targeting small molecule radiopharmaceuticals. Discover which indication is expected to grab the major GPCR-targeting therapies market share @ GPCR-Targeting Therapies Market Report GPCR-Targeting Therapies Market Dynamics The GPCR-targeting therapies market is experiencing dynamic growth, driven by advances in drug discovery technologies, an expanding understanding of GPCR biology, and the therapeutic relevance of these receptors in a wide array of diseases. GPCRs represent the largest family of membrane receptors in humans and are involved in regulating various physiological processes, making them attractive targets for drug development. Approximately 30–40% of currently approved drugs act on GPCRs, underscoring their clinical and commercial significance. One of the key market dynamics is the diversification of therapeutic areas beyond traditional indications such as cardiovascular diseases and neurological disorders. Recent research has highlighted the role of GPCRs in oncology, metabolic disorders, and immune-mediated diseases, fueling interest in developing novel ligands, biased agonists, and allosteric modulators that offer greater specificity and reduced side effects. The development of precision medicine approaches and better structural characterization of GPCRs using cryo-electron microscopy have further enabled the design of highly targeted therapies. Pharmaceutical companies are increasingly investing in GPCR-focused pipelines, often in collaboration with biotechnology firms and academic research institutions. Strategic partnerships, licensing deals, and acquisitions are common, aiming to access novel chemistries and platform technologies, such as structure-based drug design, high-throughput screening, and artificial intelligence-enabled ligand discovery. These collaborations are vital for accelerating R&D timelines and reducing attrition rates in clinical development. However, the market also faces several challenges, including the inherent complexity of GPCR signaling pathways, the risk of off-target effects, and the difficulty of achieving functional selectivity. Regulatory hurdles, high development costs, and the need for robust biomarkers for patient stratification further complicate commercialization efforts. Despite these barriers, the pipeline remains robust, with a growing number of GPCR-targeting candidates advancing through preclinical and clinical stages. Overall, the GPCR-targeting therapies market is poised for sustained expansion, supported by scientific innovation, a growing demand for targeted treatments, and the therapeutic versatility of GPCRs. With the convergence of computational biology, structural pharmacology, and translational research, the next wave of GPCR-targeting drugs is expected to offer novel mechanisms of action and improved patient outcomes across diverse indications. GPCR-Targeting Therapies Treatment Market The market outlook for GPCR-targeting therapies is promising, driven by successful drugs like ZAVZPRET, POTELIGEO, AIMOVIG, and VYEPTI. ZAVZPRET is an innovative small-molecule antagonist of the CGRP receptor, approved for the acute treatment of migraines, both with and without aura, in adults. It works by inhibiting the CGRP receptor, which plays a key role in migraine development by contributing to neurogenic inflammation and blood vessel dilation. Administered as a nasal spray, ZAVZPRET allows for quick absorption through the nasal lining, providing direct access to the bloodstream while bypassing the digestive system and first-pass liver metabolism. POTELIGEO, developed by Kyowa Kirin, is a humanized monoclonal antibody that targets the CCR4 receptor—a protein commonly found on certain cancerous T-cells. By binding to CCR4, the drug helps recruit immune cells to attack and eliminate malignant cells, thereby boosting the body's immune defense against cancer. Initially approved in Japan in 2012 for relapsed or refractory CCR4-positive adult T-cell leukemia (ATL), its indication was expanded in 2014 to include relapsed or refractory CCR4-positive peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL). The U.S. FDA approved POTELIGEO in 2018 for Mycosis Fungoides and Sézary Syndrome, with similar approvals granted in Europe. In June 2020, the drug became commercially available in Germany for adults with Mycosis Fungoides or Sézary Syndrome who had undergone at least one prior systemic treatment. Erenumab, co-developed by Amgen and Novartis, is a fully human monoclonal antibody that selectively binds to and blocks CGRP receptors. CGRP ligands, which are small neuropeptides, contribute to migraine and chronic pain through strong vasodilatory effects. By directly competing with CGRP, erenumab provides a high degree of specificity and effectiveness compared to small-molecule therapies. It is used to treat conditions such as migraine, vasoconstriction, hot flashes, and stable angina pectoris. The antibody received approval in the U.S. in May 2018 and in the EU in July 2018. Learn more about the FDA-approved GPCR-targeting therapies @ GPCR-Targeting Therapies Drugs Key Emerging GPCR-Targeting Therapies and Companies Several key players, including CytoDyn (Leronlimab), REMD Biotherapeutics (Volagidemab), Structure Therapeutics (GSBR-1290), GPCR Therapeutics (GPC-100), and others, are involved in developing drugs for GPCR-targeting therapies for various indications such as NASH, Multiple Myeloma, Diabetes, and others. Volagidemab (REMD-477) is a human monoclonal antibody targeting the glucagon receptor (GCGR), developed by REMD Biotherapeutics for the treatment of juvenile type I diabetes (T1D) and type II diabetes (T2D). It functions by binding to GCGR and competitively inhibiting its signaling pathway. This action enhances glucose uptake by the liver, reduces the breakdown of glycogen and gluconeogenesis, and stimulates glycogen synthesis—collectively contributing to its blood sugar-lowering effects (CK060182). As of March 2021, the drug was being investigated in multiple indications: T1D and T2D were in Phase II clinical trials, glucose intolerance was in Phase I, and metabolic disorders were in the preclinical stage (CK060183). Leronlimab is classified as a viral entry inhibitor, a type of HIV therapy that blocks the virus from penetrating and infecting healthy cells. In contrast to Highly Active Antiretroviral Therapy (HAART), which targets HIV after cell entry and replication, Leronlimab intervenes earlier in the viral life cycle. The critical role of the CCR5 receptor in HIV infection is highlighted by the natural immunity observed in individuals with a genetic mutation that disables CCR5 expression. Leronlimab is currently under development for the treatment of Nonalcoholic Steatohepatitis (NASH), HIV-associated NASH, and various solid tumors, with development efforts currently in Phase II. In April 2019, the company signed multiple agreements with Samsung for the transfer of technology, process validation, manufacturing, and pre-approval inspection services, aimed at supporting the commercial production of Leronlimab's bulk drug substance. The anticipated launch of these emerging therapies are poised to transform the GPCR-targeting therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the GPCR-targeting therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about GPCR-targeting therapies clinical trials, visit @ GPCR-Targeting Therapies Treatment Drugs GPCR-Targeting Therapies Overview G protein-coupled receptors (GPCRs) are a vital group of cell surface receptors that regulate numerous physiological processes. In many cancers, GPCR pathways are often dysregulated due to abnormal expression, increased activity, or mutations, contributing to uncontrolled cell growth, blood vessel formation, and metastasis. GPCRs are categorized into several classes based on their structure and function. In humans, the primary classes include Class A (Rhodopsin-like), Class B (Secretin and Adhesion), Class C (Metabotropic glutamate/pheromone), and Class F (Frizzled/TAS2). Additional classes, such as Class D (fungal mating pheromone receptors) and Class E (cyclic AMP receptors), are present in non-human organisms. Among these, Class A is the most extensive, encompassing a majority of hormone, neurotransmitter, and sensory receptors. Class B is split into secretin and adhesion subgroups, Class C comprises receptors for glutamate and GABA, and Class F includes receptors like frizzled and smoothened involved in Wnt signaling. This classification underscores the structural and functional diversity of GPCRs and their critical roles in both normal physiology and disease. GPCR-Targeting Therapies Epidemiology Segmentation The GPCR-targeting therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for GPCR-Targeting Therapies Total Eligible Patient Pool in Selected Indications for GPCR-Targeting Therapies Total Treated Cases in Selected Indications for GPCR-Targeting Therapies GPCR-Targeting Therapies Report Metrics Details Study Period 2020–2034 GPCR-Targeting Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report PTCL, CTCL, Migraine, NASH, and others Key GPCR-Targeting Therapies Companies CytoDyn, REMD Biotherapeutics, GPCR Therapeutics, Structure Therapeutics, Pfizer, Kyowa Hakko Kirin, Novartis, Amgen, Lundbeck, and others Key GPCR-Targeting Therapies Leronlimab, Volagidemab, GPC-100, GSBR-1290, ZAVZPRET, POTELIGEO, AIMOVIG, VYEPTI, and others Scope of the GPCR-Targeting Therapies Market Report GPCR-Targeting Therapies Therapeutic Assessment: GPCR-Targeting Therapies current marketed and emerging therapies GPCR-Targeting Therapies Market Dynamics: Conjoint Analysis of Emerging GPCR-Targeting Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, GPCR-Targeting Therapies Market Access and Reimbursement Discover more about GPCR-targeting therapies in development @ GPCR-Targeting Therapies Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. GPCR-Targeting Therapies Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Indications in 2020 6.2. Market Share (%) Distribution by Indications in 2034 7. GPCR-Targeting Therapies: Background and Overview 7.1. Introduction 7.2. Potential of GPCR-Targeting Therapies in Different Indications 7.3. Clinical Applications of GPCR-Targeting Therapies 8. Treatment and Management 9. Target Patient Pool of GPCR-Targeting Therapies 9.1. Assumptions and Rationale 9.2. Key Findings 9.3. Total Cases of Selected Indication for GPCR-Targeting Therapies in the 7MM 9.4. Total Eligible Patient Pool of Selected Indication for GPCR-Targeting Therapies in the 7MM 9.5. Total Treatable Cases in Selected Indication for GPCR-Targeting Therapies in the 7MM 10. Marketed Therapies 10.1. Key Competitors 10.2. OTELIGEO (mogamulizumab-kpkc): Kyowa Hakko Kirin 10.2.1. Product Description 10.2.2. Regulatory milestones 10.2.3. Other developmental activities 10.2.4. Clinical development 10.2.5. Safety and efficacy 10.3. AIMOVIG (erenumab-aooe): Novartis/Amgen 10.3.1. Product Description 10.3.2. Regulatory milestones 10.3.3. Other developmental activities 10.3.4. Clinical development 10.3.5. Safety and efficacy List to be continued in the report 11. Emerging Therapies 11.1. Key Competitors 11.2. Volagidemab: REMD Biotherapeutics 11.2.1. Product Description 11.2.2. Other developmental activities 11.2.3. Clinical development 11.2.4. Safety and efficacy 11.3. Leronlimab: CytoDyn 11.3.1. Product Description 11.3.2. Other developmental activities 11.3.3. Clinical development 11.3.4. Safety and efficacy 12. GPCR-Targeting Therapies: Seven Major Market Analysis 12.1. Key Findings 12.2. Market Outlook 12.3. Conjoint Analysis 12.4. Key Market Forecast Assumptions 12.4.1. Cost Assumptions and Rebates 12.4.2. Pricing Trends 12.4.3. Analogue Assessment 12.4.4. Launch Year and Therapy Uptakes 12.5. Total Market Sizes of GPCR-Targeting Therapies by Indications in the 7MM 12.6. The United States Market Size 12.6.1. Market Size by Indication in the United States 12.6.2. Market Size by Therapies in the United States 12.7. EU4 and the UK 12.7.1. Market Size by Indications in EU4 and the UK 12.7.2. Market Size by Therapies in EU4 and the UK 12.8. Japan 12.8.1. Market Size by Indications in Japan 12.8.2. Market Size by Therapies in Japan 13. KOL Views 14. Unmet Needs 15. Market Access and Reimbursement 16. Appendix 16.1. Bibliography 16.2. Report Methodology 17. DelveInsight Capabilities 18. Disclaimer 19. About DelveInsight Related Reports Migraine Market Migraine Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key migraine companies, including Lundbeck Seattle BioPharmaceutical, Eli Lilly and Company, Amgen, Novartis, Teva Pharmaceuticals, Allergan, Biohaven Pharmaceuticals, Dr. Reddy's Labs, AbbVie, Impel NeuroPharma, Zosano Pharma, Axsome Therapeutics, Aeon Biopharma Inc., Ionis Pharmaceuticals, Inc., Charleston Laboratories, among others. Metabolic Dysfunction-Associated Steatohepatitis Market Metabolic Dysfunction-Associated Steatohepatitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key MASH companies, including Inventiva Pharma, Novo Nordisk A/S, Cirius Therapeutics, Inc., Akero Therapeutics, Inc., 89bio, Inc., Boehringer Ingelheim, Zealand Pharma, Galectin Therapeutics Inc., Lipocine Inc., Viking Therapeutics, Inc., Eli Lilly and Company, Boston Pharmaceuticals, Pfizer, HighTide Biopharma, CytoDyn, Inc., Merck & Co., Hanmi Pharmaceutical, Hepagene (Shanghai) Co., Ltd., Hepion Pharmaceuticals, Inc., Enyo Pharmaceuticals, Gilead Sciences, Poxel SA, Zydus Therapeutics, Sagimet Biosciences Inc., Ionis Pharmaceuticals, Corcept Therapeutics, among others. Cutaneous T-Cell Lymphoma Market Cutaneous T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CTCL companies, including Pfizer, Helsinn Therapeutics, Kyowa Hakko Kirin, Citius Pharmaceuticals, Soligenix, Prescient Therapeutics, Innate Pharma, Bristol-Myers Squibb, BioInvent International AB, among others. Peripheral T-Cell Lymphoma Market Peripheral T-Cell Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key PTCL companies, including Secura Bio, Shanghai YingLi Pharmaceutical, Dizal Pharmaceuticals, Viracta Therapeutics, Innate Pharma, CStone Pharmaceuticals, Affimed, Otsuka Pharmaceutical, Astex Pharmaceuticals, Autolus, Myeloid Therapeutics, Merck Sharp & Dohme, Bristol Myers Squibb, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact Us Shruti Thakur info@ +14699457679 Logo: View original content:
Globe and Mail
a day ago
- Business
- Globe and Mail
GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim
DelveInsight's 'CTD-ILD Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the CTD-ILD, historical and forecasted epidemiology as well as the CTD-ILD market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. The latest healthcare forecast report provides an in-depth analysis of CTD-ILD, offering comprehensive insights into the CTD-ILD revenue trends, prevalence, and treatment landscape. The report delves into key CTD-ILD statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging CTD-ILD therapies. Additionally, we cover the landscape of CTD-ILD clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of CTD-ILD treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the CTD-ILD space. The CTD-ILD market size was valued ~USD 1,498 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034) In 2023, the United States held the largest market share for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), contributing approximately 70% of the total market size across the 7MM. This was significantly higher compared to other key markets, including the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan. In 2023, Germany recorded the largest market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) among EU countries, reaching nearly USD 84 million, while Spain had the smallest market size at USD 38 million. Japan's market size for Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD) was approximately USD 136 million in 2023, representing 9% of the total market across the 7MM. Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others The CTD-ILD market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage CTD-ILD pipeline products will significantly revolutionize the CTD-ILD market dynamics. According to DelveInsight's evaluation, the total prevalent cases of Interstitial Lung Disease (ILD) in the 7MM were approximately 1,662,000 in 2023. In 2023, the United States recorded the highest number of diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), approximately 132,000, with numbers anticipated to increase in the future. Within Europe, the UK reported the highest number of diagnosed prevalent cases of CTD-ILD in 2023, approximately 27,000, followed by Germany with 25,000 cases. In contrast, Spain had the lowest prevalence, with around 11,000 cases. In 2023, Japan reported approximately 68,000 diagnosed prevalent cases of Connective Tissue Disease associated with Interstitial Lung Disease (CTD-ILD), representing around 23% of the total cases across the 7MM. In the US in 2023, type-specific diagnosed cases of CTD-ILD were highest for pSS-ILD (approximately 38,000), followed by SSc-ILD (around 31,000), Other CTD-ILDs (roughly 30,000), RA-ILD (about 20,000), DM-ILD/PM-ILD (close to 8,000), and SLE-ILD (nearly 5,000). Connective Tissue Disease associated with Interstitial Lung Disease Overview Connective Tissue Disease (CTD)-associated Interstitial Lung Disease (ILD) refers to a group of lung disorders that occur as a result of underlying connective tissue diseases. These diseases, such as rheumatoid arthritis, systemic lupus erythematosus, scleroderma, and polymyositis, can cause inflammation and scarring in the lungs, leading to ILD. This condition results in impaired lung function, breathing difficulties, and decreased oxygen levels. The damage is often progressive and can lead to respiratory failure if left untreated. Early diagnosis and management are crucial to managing symptoms and slowing disease progression. Treatment typically involves immunosuppressive medications and management of the underlying CTD. CTD-ILD Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Connective Tissue Disease associated with Interstitial Lung Disease Epidemiology Segmentation: The CTD-ILD market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into: Download the report to understand which factors are driving CTD-ILD epidemiology trends @ CTD-ILD Epidemiology Forecast CTD-ILD Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the CTD-ILD market or expected to get launched during the study period. The analysis covers CTD-ILD market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the CTD-ILD Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. CTD-ILD Therapies and Key Companies Belimumab: GlaxoSmithKline bosentan: Actelion Tulisokibart: Prometheus Biosciences Rituximab: Eric Matteson Vixarelimab: Genentech, Inc. OFEV: Boehringer Ingelheim Pharmaceuticals, Inc. Belimumab, GSK1550188 (BENLYSTA): GlaxoSmithKline plc. Connective Tissue Disease associated with Interstitial Lung Disease Market Drivers Increasing Prevalence of CTD-ILD Advances in Diagnostic Techniques Emergence of Novel Therapies Rising Awareness Among Healthcare Providers Aging Population Regulatory Approvals for Targeted Treatments Supportive Healthcare Policies Connective Tissue Disease associated with Interstitial Lung Disease Market Barriers High Cost of Treatment Limited Drug Approvals Challenges in Early Diagnosis Heterogeneity of CTD-ILD Side Effects of Current Treatments Lack of Awareness in Emerging Markets Inconsistent Clinical Guidelines Scope of the Connective Tissue Disease associated with Interstitial Lung Disease Market Report Study Period: 2020–2034 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key CTD-ILD Companies: GlaxoSmithKline, Actelion, Prometheus Biosciences, Eric Matteson, Genentech, Inc., Boehringer Ingelheim Pharmaceuticals, and others Key CTD-ILD Therapies: Belimumab, bosentan, Tulisokibart, Rituximab, Vixarelimab, OFEV, Belimumab, GSK1550188 (BENLYSTA), and others CTD-ILD Therapeutic Assessment: CTD-ILD current marketed and CTD-ILD emerging therapies CTD-ILD Market Dynamics: CTD-ILD market drivers and CTD-ILD market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Table of Contents 1. CTD-ILD Market Report Introduction 2. Executive Summary for CTD-ILD 3. SWOT analysis of CTD-ILD 4. CTD-ILD Patient Share (%) Overview at a Glance 5. CTD-ILD Market Overview at a Glance 6. CTD-ILD Disease Background and Overview 7. CTD-ILD Epidemiology and Patient Population 8. Country-Specific Patient Population of CTD-ILD 9. CTD-ILD Current Treatment and Medical Practices 10. CTD-ILD Unmet Needs 11. CTD-ILD Emerging Therapies 12. CTD-ILD Market Outlook 13. Country-Wise CTD-ILD Market Analysis (2020–2034) 14. CTD-ILD Market Access and Reimbursement of Therapies 15. CTD-ILD Market Drivers 16. CTD-ILD Market Barriers 17. CTD-ILD Appendix 18. CTD-ILD Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
6 days ago
- Health
- Yahoo
DHODH Inhibitors Market Forecast to Reach New Heights by 2034 Owing to the Expanding Applications in Oncology and Autoimmune Diseases
The DHODH inhibitor market is poised for steady growth, fueled by the rising burden of autoimmune and inflammatory diseases, along with increasing interest in targeting metabolic pathways in oncology and Immunology. While only two agents, leflunomide and teriflunomide, are currently approved, a growing clinical pipeline featuring candidates from companies like Immunic Therapeutics, Jabez Bioscience, and others suggests expanded therapeutic potential beyond traditional autoimmune indications. LAS VEGAS, June 25, 2025 /PRNewswire/ -- DelveInsight's DHODH Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging DHODH inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the DHODH Inhibitors Market Report As per DelveInsight's analysis, the total market size of DHODH inhibitors in the 7MM is expected to surge significantly by 2034. The report provides the total potential number of patients in the indications, such as multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections. Leading DHODH inhibitors companies, such as Immunic Therapeutics, Aslan Pharmaceuticals, Jabez Bioscience, and others, are developing novel DHODH inhibitors that can be available in the DHODH inhibitors market in the coming years. Some of the key DHODH inhibitors in the pipeline include Vidofludimus Calcium (IMU-838), Farudodstat, JBZ-001, and others. Discover which indication is expected to grab the major DHODH inhibitors market share @ DHODH Inhibitors Market Report DHODH Inhibitors Market Dynamics The dihydroorotate dehydrogenase (DHODH) inhibitors market is witnessing growing interest due to the enzyme's critical role in the de novo pyrimidine biosynthesis pathway, which is essential for DNA and RNA synthesis. DHODH inhibitors block this mitochondrial enzyme, thereby curbing nucleotide synthesis and impeding the proliferation of rapidly dividing cells. This mechanism has significant therapeutic potential, particularly in oncology, autoimmune diseases, and viral infections. As a result, pharmaceutical companies are increasingly investing in the research and development of novel DHODH inhibitors, both as monotherapies and in combination with other agents. One of the major drivers of this market is the increased focus on targeted therapies in cancer treatment. Moreover, recent research indicates potential synergy when DHODH inhibitors are combined with other agents like BCL-2 or FLT3 inhibitors, opening avenues for combination therapies that may overcome resistance and improve patient outcomes. Additionally, the repurposing of DHODH inhibitors, such as leflunomide, initially developed for autoimmune diseases, has further catalyzed interest in this class of drugs. On the other hand, market growth is constrained by several challenges. The specificity and safety profiles of DHODH inhibitors remain areas of concern, as off-target effects or immunosuppressive consequences could limit their utility. Furthermore, competition from other targeted therapies and small molecules with established clinical efficacy can make market penetration difficult for newer DHODH inhibitors. Regulatory hurdles and the need for biomarker-driven patient stratification also add complexity to development and commercialization efforts. Looking forward, the DHODH inhibitor market is poised for steady growth, propelled by advancements in molecular biology, increasing unmet medical needs in oncology and autoimmune conditions, and the evolving landscape of precision medicine. Strategic partnerships, licensing deals, and successful late-stage trials will be critical in shaping the commercial success of emerging candidates. As the field matures, the development of next-generation DHODH inhibitors with enhanced selectivity and fewer side effects will be essential for capturing greater market share and achieving long-term clinical and commercial impact. DHODH Inhibitors Treatment Market In recent years, DHODH inhibitors have gained attention as a promising treatment strategy for chronic inflammatory and autoimmune disorders, including multiple sclerosis, ulcerative colitis, rheumatoid arthritis, and non-Hodgkin lymphoma. By targeting de novo pyrimidine synthesis, these agents effectively modulate immune responses, offering potential as disease-modifying therapies. Currently, only two DHODH inhibitors have been approved: leflunomide and its active metabolite, teriflunomide. Leflunomide, available generically, is mainly prescribed for rheumatoid arthritis, while teriflunomide, marketed as AUBAGIO, is approved for multiple sclerosis and became available in generic form in 2023. No other agents in this class have received regulatory approval so far. However, a number of novel candidates are undergoing clinical trials for autoimmune conditions, cancers, and viral infections, reflecting a growing interest in the target. Ongoing clinical results continue to demonstrate their potential, reinforcing the role of DHODH inhibitors as promising additions to the immunology drug pipeline. Learn more about the DHODH inhibitors @ DHODH Inhibitors Analysis Key Emerging DHODH Inhibitors and Companies Some of the emerging DHODH inhibitors in the pipeline include Vidofludimus Calcium (IMU-838) (Immunic Therapeutics), Farudodstat (Aslan Pharmaceuticals), JBZ-001 (Jabez Bioscience), and others. Vidofludimus calcium is an investigational oral small-molecule drug being developed as a next-generation therapy for multiple sclerosis and various chronic inflammatory and autoimmune conditions. It functions as a selective immune modulator by activating the neuroprotective transcription factor Nurr1 (nuclear receptor-related 1), which plays a role in promoting nerve cell protection. Additionally, the compound is a potent and selective inhibitor of the enzyme DHODH, essential for the metabolic processes of overactive immune and virus-infected cells. This dual mechanism contributes to its anti-inflammatory and antiviral properties. Also known as IMU-838, the drug is currently being evaluated in Phase III and Phase II clinical trials for relapsing and progressive forms of multiple sclerosis, respectively. It has shown therapeutic benefit in earlier Phase II trials across relapsing-remitting multiple sclerosis, progressive multiple sclerosis, and moderate-to-severe ulcerative colitis. JBZ-001 is another orally available small-molecule DHODH inhibitor, developed to interfere with the de novo pyrimidine nucleotide biosynthesis pathway, an essential process for the proliferation of cancer cells. By inhibiting DHODH, the pathway's rate-limiting enzyme, JBZ-001 has demonstrated cytotoxic potential against tumor cells, positioning it as a promising candidate in oncology. The compound, developed under Jabez Biosciences' translational research efforts, received FDA clearance for a commercial IND application in 2024 and is currently in Phase I trials for advanced solid tumors and hematologic cancers. The anticipated launch of these emerging therapies are poised to transform the DHODH inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the DHODH inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about DHODH inhibitors clinical trials, visit @ DHODH Inhibitors Treatment DHODH Inhibitors Overview DHODH inhibitors are a group of drugs that target and block the activity of the DHODH enzyme, which plays a vital role in the mitochondrial pathway responsible for de novo pyrimidine synthesis, crucial building blocks for DNA and RNA. By disrupting this process, these drugs reduce the supply of pyrimidines, thereby hindering DNA production and triggering cell cycle arrest, especially in fast-dividing cells. These agents are primarily used in conditions marked by excessive immune response or abnormal cell growth. In autoimmune diseases such as rheumatoid arthritis and multiple sclerosis, they help restrain the proliferation of overactive immune cells. In cancer, DHODH inhibitors are under investigation for their ability to impede tumor growth, as cancer cells depend heavily on continuous nucleotide production. This targeted mode of action makes DHODH inhibitors a promising therapeutic option for managing various diseases driven by uncontrolled cell proliferation. DHODH Inhibitors Epidemiology Segmentation The DHODH inhibitors market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for DHODH Inhibitors Total Eligible Patient Pool in Selected Indications for DHODH Inhibitors Total Treated Cases in Selected Indications for DHODH Inhibitors DHODH Inhibitors Report Metrics Details Study Period 2020–2034 DHODH Inhibitors Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report Multiple sclerosis, ulcerative colitis, rheumatoid arthritis, NHL, and even viral infections Key DHODH Inhibitors Companies Immunic Therapeutics, Aslan Pharmaceuticals, Jabez Bioscience, and others Key DHODH Inhibitors Vidofludimus Calcium (IMU-838), Farudodstat, JBZ-001, leflunomide and teriflunomide (AUBAGIO, generic since 2023), and others Scope of the DHODH Inhibitors Market Report DHODH Inhibitors Therapeutic Assessment: DHODH Inhibitors current marketed and emerging therapies DHODH Inhibitors Market Dynamics: Conjoint Analysis of Emerging DHODH Inhibitors Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, DHODH Inhibitors Market Access and Reimbursement Discover more about DHODH inhibitors in development @ DHODH Inhibitors Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. DHODH Inhibitors Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. DHODH Inhibitors: Background and Overview 7.1. Introduction 7.2. Potential of DHODH Inhibitors in Different Indications 7.3. Clinical Applications of DHODH Inhibitors 8. Target Patient Pool of DHODH Inhibitors 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for DHODH Inhibitors in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for DHODH Inhibitors in the 7MM 8.5. Total Treatable Cases in Selected Indications for DHODH Inhibitors in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. Vidofludimus Calcium (IMU-838): Immunic Therapeutics 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.3. JBZ-001: Jabez Bioscience 9.3.1. Product Description 9.3.2. Other developmental activities 9.3.3. Clinical development 9.3.4. Safety and efficacy List to be continued in the report 10. DHODH Inhibitors: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Sizes of DHODH Inhibitors by Indications in the 7MM 10.6. The United States Market Size 10.6.1. Total Market Size of DHODH Inhibitors in the United States 10.6.2. Market Size of DHODH Inhibitors by Indication in the United States 10.6.3. Market Size of DHODH Inhibitors by Therapies in the United States 10.7. EU4 and the UK 10.7.1. Total Market Size of DHODH Inhibitors in EU4 and the UK 10.7.2. Market Size of DHODH Inhibitors by Indications in EU4 and the UK 10.7.3. Market Size of DHODH Inhibitors by Therapies in EU4 and the UK 10.8. Japan 10.8.1. Total Market Size of DHODH Inhibitors in Japan 10.8.2. Market Size of DHODH Inhibitors by Indications in Japan 10.8.3. Market Size of DHODH Inhibitors by Therapies in Japan 11. SWOT Analysis 12. KOL Views 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight Related Reports Ulcerative Colitis Market Ulcerative Colitis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ulcerative colitis companies, including Arena Pharmaceuticals, Pfizer, Abivax, Reistone Biopharma, InDex Pharmaceuticals, AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, NImmune, Merck, Mesoblast, among others. Non-Hodgkin's Lymphoma Market Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key NHL companies, including AbbVie, Genmab, Novartis, Angiocrine Bioscience, Autolus, Zentera Therapeutics, Jiangsu Hengrui Medicine, among others. Multiple Sclerosis Market Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key multiple sclerosis companies, including Novartis, Sanofi, AB Science, Roche, Clene Nanomedicine, InnoCare Pharma, among others. Rheumatoid Arthritis Market Rheumatoid Arthritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key rheumatoid arthritis companies, including R-Pharm, Taisho Pharmaceuticals, GlaxoSmithKline, Aclaris Therapeutics, Bristol Myers Squibb, Eli Lilly, Taiho Pharmaceutical, Cyxone, Gilead Sciences, Kiniksa Pharmaceuticals, Istesso, Applied Molecular Transport, Horizon Therapeutics, Genosco (Oscotec), Hope Biosciences, Abivax, Mesoblast, Akros Pharma, Japan Tobacco, Pfizer, Philogen, AbbVie, Pfizer, SynAct Pharma, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
7 days ago
- Business
- Yahoo
BAFF- and APRIL-targeted Therapies Market Sees Surge in Activity Amid Rising Autoimmune Disease Burden
The BAFF- and APRIL-targeted therapies market is experiencing steady growth driven by the rising prevalence of autoimmune diseases such as systemic lupus erythematosus (SLE), IgA nephropathy, and Sjögren's syndrome. Advancements in biologics and the entry of pipeline agents with improved efficacy profiles are further fueling market expansion. LAS VEGAS, June 24, 2025 /PRNewswire/ -- DelveInsight's BAFF- and APRIL-targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging BAFF- and APRIL-targeted therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM. Key Takeaways from the BAFF- and APRIL-targeted Therapies Market Report As per DelveInsight's analysis, the total market size of BAFF- and APRIL-targeted therapies in the 7MM is expected to surge significantly by 2034. BAFF and APRIL-targeted therapies are actively being developed to address a broad spectrum of autoimmune diseases, including IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions, offering promising new options to modulate pathogenic B-cell activity and improve patient outcomes. Leading BAFF- and APRIL-targeted therapies companies, such as Vera Therapeutics, RemeGen, Aurinia Pharmaceuticals, and others, are developing novel BAFF- and APRIL-targeted therapies that can be available in the BAFF- and APRIL-targeted therapies market in the coming years. Some of the key BAFF- and APRIL-targeted therapies in the pipeline include Atacicept, Telitacicept, AUR200, and others. In May 2025, Vera Therapeutics announced that primary endpoint results from the pivotal Phase III ORIGIN 3 trial of atacicept in Immunoglobulin A Nephropathy (IgAN) are expected in Q2 2025, with plans to submit a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) in Q4 2025 for accelerated approval, targeting a potential PDUFA date and commercial launch in 2026. In November 2024, the European Medicines Agency (EMA) granted orphan medicine designation to Atacicept for the treatment of IgAN. In May 2024, Vera Therapeutics announced that the US FDA had granted Breakthrough Therapy Designation (BTD) to atacicept for the treatment of IgAN. The designation reflects the FDA's determination that, based on an assessment of data from the Phase IIb ORIGIN clinical trial of atacicept for IgAN, atacicept may demonstrate substantial improvement on a clinically significant endpoint over available therapies for patients with IgAN. Discover which indication is expected to grab the major BAFF- and APRIL-targeted therapies market share @ BAFF- and APRIL-targeted Therapies Market Report BAFF- and APRIL-targeted Therapies Market Dynamics The BAFF- and APRIL-targeted therapies market is evolving rapidly, driven by a growing understanding of B-cell biology and its role in autoimmune diseases. BAFF and APRIL are crucial for B-cell survival, maturation, and function. Overexpression of these cytokines has been implicated in diseases such as IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions. Therapies targeting these pathways aim to modulate abnormal B-cell activity, offering more precise immunomodulatory approaches compared to broad immunosuppressants. Market interest in this space has intensified with the development of biologics like atacicept and, more recently, telitacicept. These agents work by neutralizing excess BAFF and/or APRIL, reducing pathogenic autoantibody production. The differentiated mechanism of dual targeting is believed to offer superior efficacy in certain patient subtypes, fueling competitive development programs. The market dynamics are shaped by both unmet clinical needs and strategic commercial considerations. Autoimmune diseases, particularly lupus and IgAN, have long suffered from limited treatment options with poor tolerability or efficacy. As a result, payers and clinicians are keen on alternatives that offer disease modification and long-term remission. However, safety remains a concern, especially the risk of hypogammaglobulinemia and infections due to B-cell suppression. This risk-benefit balance is a key differentiator in positioning products within the competitive landscape. Overall, the BAFF/APRIL-targeted therapy market is transitioning from experimental to established, with first-in-class and best-in-class competition intensifying. Pipeline diversity, biomarker-driven patient selection, and combinatorial strategies with other immunotherapies will be central to shaping the future landscape. As real-world evidence accumulates and regulatory agencies refine guidance, these therapies may move from niche indications to broader frontline use in autoimmune care. BAFF- and APRIL-targeted Therapies Treatment Market The landscape for BAFF- and APRIL-targeted therapies is undergoing rapid transformation, fueled by the pressing need for more precise B cell modulation in autoimmune disorders. As of 2025, no fusion proteins targeting these pathways have received FDA approval, but several promising candidates are advancing through late-stage clinical trials. This progress reflects a positive shift in the field, pointing toward more effective dual-pathway immunotherapies that could address the shortcomings of existing treatments and provide renewed hope for patients with challenging autoimmune conditions. Learn more about the BAFF- and APRIL-targeted therapies @ BAFF- and APRIL-targeted Therapies Analysis Key Emerging BAFF- and APRIL-targeted Therapies and Companies Some of the BAFF- and APRIL-targeted therapies in the pipeline include Atacicept (Vera Therapeutics), Telitacicept (RemeGen), AUR200 (Aurinia Pharmaceuticals), and others. Atacicept is an investigational fusion protein composed of the soluble form of the TACI receptor, which binds to the cytokines BAFF and APRIL—members of the TNF family involved in supporting B-cell survival and promoting the production of autoantibodies linked to autoimmune conditions such as IgAN and lupus nephritis. Vera Therapeutics views atacicept as a strong contender for best-in-class status due to its dual targeting of B cells and plasma cells to lower autoantibody levels. The drug has already been tested in over 1,500 patients across multiple indications in clinical trials. Atacicept is currently undergoing Phase III trials for the treatment of IgAN. Telitacicept, developed by RemeGen, is another fusion protein that also targets BAFF and APRIL, aiming to treat autoimmune diseases driven by B cells. It is being studied globally, including in the U.S., for conditions such as myasthenia gravis, systemic lupus erythematosus (SLE), and Sjögren's syndrome. The U.S. FDA has granted Orphan Drug Designation (ODD) and Fast Track Designation (FTD) for telitacicept in myasthenia gravis. A notable advancement in its development came in August 2024, when the first U.S. patient was enrolled in a global Phase III trial for generalized myasthenia gravis. The anticipated launch of these emerging therapies are poised to transform the BAFF- and APRIL-targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the BAFF- and APRIL-targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth. To know more about BAFF- and APRIL-targeted therapies clinical trials, visit @ BAFF- and APRIL-targeted Therapies Treatment BAFF- and APRIL-targeted Therapies Overview BAFF and APRIL, both part of the TNF family, are key regulators of B cell survival, development, and antibody class switching through their interactions with the receptors BAFF-R, TACI, and BCMA. When the BAFF/APRIL pathway becomes dysregulated, often due to ligand overexpression, it can trigger abnormal B cell activation and drive the development of autoimmune diseases. BAFF mainly signals through BAFF-R, activating both the classical and alternative NF-κB pathways, while APRIL binds to TACI and BCMA and also interacts with heparan sulfate proteoglycans to amplify B cell responses. Given their pivotal role in immune system regulation, BAFF and APRIL have emerged as promising therapeutic targets. Clinical studies have shown that inhibiting BAFF can significantly reduce disease activity in various autoimmune conditions by curbing harmful B-cell activity and helping to restore immune homeostasis. BAFF- and APRIL-targeted Therapies Epidemiology Segmentation The BAFF- and APRIL-targeted therapies market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into: Total Cases in Selected Indications for BAFF- and APRIL-targeted Therapies Total Eligible Patient Pool in Selected Indications for BAFF- and APRIL-targeted Therapies Total Treated Cases in Selected Indications for BAFF- and APRIL-targeted Therapies BAFF- and APRIL-targeted Therapies Report Metrics Details Study Period 2020–2034 BAFF- and APRIL-targeted Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] Key Indications Covered in the Report IgA nephropathy (IgAN), lupus nephritis, myasthenia gravis, systemic lupus erythematosus (SLE), Sjögren's syndrome, and other B-cell-mediated autoimmune conditions Key BAFF- and APRIL-targeted Therapies Companies Vera Therapeutics, RemeGen, Aurinia Pharmaceuticals, and others Key BAFF- and APRIL-targeted Therapies Atacicept, Telitacicept, AUR200, and others Scope of the BAFF- and APRIL-targeted Therapies Market Report BAFF- and APRIL-targeted Therapies Therapeutic Assessment: BAFF- and APRIL-targeted Therapies current marketed and emerging therapies BAFF- and APRIL-targeted Therapies Market Dynamics: Conjoint Analysis of Emerging BAFF- and APRIL-targeted Therapies Drugs Competitive Intelligence Analysis: SWOT analysis and Market entry strategies Unmet Needs, KOL's views, Analyst's views, BAFF- and APRIL-targeted Therapies Market Access and Reimbursement Discover more about BAFF- and APRIL-targeted therapies in development @ BAFF- and APRIL-targeted Therapies Clinical Trials Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Key Events 5. Epidemiology and Market Forecast Methodology 6. BAFF- and APRIL-targeted Therapies Market Overview at a Glance in the 7MM 6.1. Market Share (%) Distribution by Therapies in 2025 6.2. Market Share (%) Distribution by Therapies in 2034 6.3. Market Share (%) Distribution by Indications in 2025 6.4. Market Share (%) Distribution by Indications in 2034 7. BAFF- and APRIL-targeted Therapies: Background and Overview 7.1. Introduction 7.2. Potential of BAFF- and APRIL-targeted Therapies in Different Indications 7.3. Clinical Applications of BAFF- and APRIL-targeted Therapies 8. Target Patient Pool of BAFF- and APRIL-targeted Therapies 8.1. Assumptions and Rationale 8.2. Key Findings 8.3. Total Cases of Selected Indication for BAFF- and APRIL-targeted Therapies in the 7MM 8.4. Total Eligible Patient Pool of Selected Indication for BAFF- and APRIL-targeted Therapies in the 7MM 8.5. Total Treatable Cases in Selected Indication for BAFF- and APRIL-targeted Therapies in the 7MM 9. Emerging Therapies 9.1. Key Competitors 9.2. Atacicept: Vera Therapeutics 9.2.1. Product Description 9.2.2. Other developmental activities 9.2.3. Clinical development 9.2.4. Safety and efficacy 9.3. Telitacicept: RemeGen 9.3.1. Product Description 9.3.2. Other developmental activities 9.3.3. Clinical development 9.3.4. Safety and efficacy List to be continued in the report 10. BAFF- and APRIL-targeted Therapies: Seven Major Market Analysis 10.1. Key Findings 10.2. Market Outlook 10.3. Conjoint Analysis 10.4. Key Market Forecast Assumptions 10.4.1. Cost Assumptions and Rebates 10.4.2. Pricing Trends 10.4.3. Analogue Assessment 10.4.4. Launch Year and Therapy Uptakes 10.5. Total Market Sizes of BAFF- and APRIL-targeted Therapies by Indications in the 7MM 10.6. The United States Market Size 10.6.1. Total Market Size of BAFF- and APRIL-targeted Therapies in the United States 10.6.2. Market Size of BAFF- and APRIL-targeted Therapies by Indication in the United States 10.6.3. Market Size of BAFF- and APRIL-targeted Therapies by Therapies in the United States 10.7. EU4 and the UK 10.7.1. Total Market Size of BAFF- and APRIL-targeted Therapies in EU4 and the UK 10.7.2. Market Size of BAFF- and APRIL-targeted Therapies by Indications in EU4 and the UK 10.7.3. Market Size of BAFF- and APRIL-targeted Therapies by Therapies in EU4 and the UK 10.8. Japan 10.8.1. Total Market Size of BAFF- and APRIL-targeted Therapies Inhibitors in Japan 10.8.2. Market Size of BAFF- and APRIL-targeted Therapies by Indications in Japan 10.8.3. Market Size of BAFF- and APRIL-targeted Therapies by Therapies in Japan 11. SWOT Analysis 12. KOL Views 13. Unmet Needs 14. Market Access and Reimbursement 15. Appendix 15.1. Bibliography 15.2. Report Methodology 16. DelveInsight Capabilities 17. Disclaimer 18. About DelveInsight Related Reports Sjogren's Syndrome Market Sjogren's Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Sjogren's syndrome companies, including Advanz Pharma, Daiichi Sankyo, Resolve Therapeutics, GlaxoSmithKline, VIELABIO, RemeGen, Bristol Myers Squibb, TearSolutions, Pfizer Inc., AstraZeneca plc, Novartis AG, Sanofi S.A., Roche Holding AG, Johnson & Johnson, AbbVie Inc., Eli Lilly and Company, Biogen Inc., Amgen Inc., Celgene Corporation, Genentech, Inc., Boehringer Ingelheim International GmbH, Takeda Pharmaceutical, Gilead Sciences, Inc., Merck & Co., Vertex Pharmaceuticals, Bayer AG, among others. Systemic Lupus Erythematosus Market Systemic Lupus Erythematosus Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key SLE companies, including Biogen, Novartis, MorphoSys, Idorsia Pharmaceuticals, Viatris, RemeGen, UCB Pharma, Genentech, Bristol Myers Squibb, AbbVie, among others. Lupus Nephritis Market Lupus Nephritis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key lupus nephritis companies, including Hoffmann-La Roche, Chugai Pharmaceutical, Novartis Pharmaceuticals, among others. IgA Nephropathy Market IgA Nephropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key IgAN companies, including Novartis, F. Hoffmann-La Roche, Ionis Pharmaceuticals, AstraZeneca (Alexion Pharmaceuticals), Vertex Pharmaceuticals, Otsuka Pharmaceutical, Biogen, Arrowhead Pharmaceuticals, NovelMed, Q32 Bio, Walden Biosciences, Takeda Pharmaceutical, Vera Therapeutics, among others. About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve. Contact UsShruti Thakur info@ +14699457679 Logo: View original content: SOURCE DelveInsight Business Research, LLP Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Globe and Mail
23-06-2025
- Health
- Globe and Mail
Postoperative Pain Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis
"Postoperative Pain Pipeline Insight" DelveInsight's, 'Postoperative Pain - Pipeline Insight, 2025' report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Postoperative Pain pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Postoperative Pain Pipeline constitutes 45+ key companies continuously working towards developing 50+ Postoperative Pain treatment therapies, analyzes DelveInsight. Postoperative Pain Overview: Postoperative or postsurgical pain is defined as pain persisting for more than 3 to 6 months after surgery, differing in nature and location from any pre-surgical pain. It is often associated with neuropathic pain caused by surgical injury to major peripheral nerves. While any surgery can result in persistent postoperative pain (PPP), procedures like inguinal hernia repair and thoracic surgery, leg amputation, and coronary artery bypass surgery are at higher risk due to potential nerve damage. Surgical techniques that minimize nerve injury are critical to reducing this risk. Postoperative pain is categorized as acute (up to 7 days post-surgery) or chronic (lasting over 3 months), arising from cutaneous, deep somatic, or visceral structures. "Postoperative Pain Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Postoperative Pain Therapeutics Market. Key Takeaways from the Postoperative Pain Pipeline Report DelveInsight's Postoperative Pain pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Postoperative Pain treatment. In August 2024, Mylan Specialty, LP announced that MR-107A-02 is being evaluated for its safety and efficacy in treating acute pain following herniorrhaphy. In August 2024, Jiangsu HengRui Medicine Co., Ltd. disclosed an ongoing study to assess the safety and effectiveness of bupivacaine liposome injection for local infiltration analgesia in pediatric orthopedic surgeries under real-world conditions. In June 2024, Johnson & Johnson Consumer Inc. announced a study aimed at determining the effectiveness of a fixed-dose combination of acetaminophen and naproxen sodium compared to a placebo in reducing pain over a 48-hour period through multiple doses. In March 2024, Formosa Pharmaceuticals and AimMax Therapeutics received FDA approval for clobetasol propionate ophthalmic suspension 0.05% (APP13007) to treat postoperative inflammation and pain after ocular surgery. Key Postoperative Pain companies such as Vivozon Pharmaceutical Inc., LipoCure, InSitu Biologics, and others are evaluating new drugs for Postoperative Pain to improve the treatment landscape. Promising Postoperative Pain pipeline therapies in various stages of development include VVZ-149, LC-400, INSB-200, and others. Postoperative Pain Pipeline Analysis The report provides insights into: The report provides detailed insights into the key companies that are developing therapies in the Postoperative Pain Market. The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Postoperative Pain treatment. It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Postoperative Pain market. Download our free sample report @ Postoperative Pain Companies There are approx. 45+ key companies which are developing the therapies for Postoperative Pain. The companies which have their Postoperative Pain drug candidates in the most advanced stage, i.e. phase III include, Vivozon Pharmaceutical Inc. DelveInsight's report covers around 22+ products under different phases of clinical development like Late stage products (Phase III) Mid-stage products (Phase II) Early-stage product (Phase I) along with the details of Pre-clinical and Discovery stage candidates Discontinued & Inactive candidates Postoperative Pain pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intravenous Subcutaneous Oral Intramuscular Tropical Postoperative Pain Products have been categorized under various Molecule types such as Monoclonal Antibody Peptides Polymer Small molecule Gene therapy Download Sample Pages to Get an in-depth Assessment of the Emerging Postoperative Pain Therapies and Key Companies: Postoperative Pain Clinical Trials and advancements Postoperative Pain Pipeline Therapeutic Assessment • Postoperative Pain Assessment by Product Type • Postoperative Pain By Stage • Postoperative Pain Assessment by Route of Administration • Postoperative Pain Assessment by Molecule Type Download Postoperative Pain Sample report to know in detail about the Postoperative Pain treatment market @ Postoperative Pain Therapeutic Assessment Table of Content 1. Report Introduction 2. Executive Summary 3. Postoperative Pain Current Treatment Patterns 4. Postoperative Pain - DelveInsight's Analytical Perspective 5. Therapeutic Assessment 6. Postoperative Pain Late-Stage Products (Phase-III) 7. Postoperative Pain Mid-Stage Products (Phase-II) 8. Early Stage Products (Phase-I) 9. Pre-clinical Products and Discovery Stage Products 10. Inactive Products 11. Dormant Products 12. Postoperative Pain Discontinued Products 13. Postoperative Pain Product Profiles 14. Postoperative Pain Key Companies 15. Postoperative Pain Key Products 16. Dormant and Discontinued Products 17. Postoperative Pain Unmet Needs 18. Postoperative Pain Future Perspectives 19. Postoperative Pain Analyst Review 20. Appendix 21. Report Methodology Request the Sample PDF to Get Detailed Insights About the Postoperative Pain Pipeline Reports Offerings: Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Kritika Rehani Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: Nevada Country: United States Website:
